Brief: I-Mab Randomized Phase 2 Study Of Uliledlimab In Combination With Pembrolizumab Plus Chemotherapy Expected To Begin In 1H 2025

NovaBridge Biosciences

10/09/2024 12:46

Sept 10 (Reuters) - I-Mab  IMAB.O :
    * I-MAB: RANDOMIZED PHASE 2 STUDY OF ULILEDLIMAB IN
COMBINATION
WITH PEMBROLIZUMAB PLUS CHEMOTHERAPY EXPECTED TO BEGIN IN 1H
2025

Source text for Eikon:  ID:nPn9wDWJ1a 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))